Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

27 mai 2026 mis à jour par: Exelixis

The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

5000

Phase

Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Nom: Exelixis Clinical Trials
Numéro de téléphone: 1-888-EXELIXIS (888-393-5494)
E-mail: druginfo@exelixis.com

Sauvegarde des contacts de l'étude

Nom: Backup or International
Numéro de téléphone: 650-837-7400

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

Enfant
Adulte
Adulte plus âgé

Accepte les volontaires sains

Non

La description

Key Inclusion Criteria:

Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation/withdrawal criteria).
Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator.
Able to comply with the long-term extension study protocol as determined by the investigator.
Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study.

Key Exclusion Criteria:

Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study.
Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant.
Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study.
Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable).
Concurrent participation in any therapeutic clinical trial (other than the parent study).

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Objectif principal: Traitement
Répartition: N / A
Modèle interventionnel: Affectation à un seul groupe
Masquage: Aucun (étiquette ouverte)

Nombre de bras

Armes et Interventions

Groupe de participants / Bras	Intervention / Traitement
Expérimental: Cabozantinib/Zanzalintinib Depending on the study treatment received in the parent study, participants may receive cabozantinib alone or in combination with other agents; zanzalintinib alone or in combination with other agents, or comparator.	Médicament: Cabozantinib Administered as specified in the parent study. Autres noms: Cabométyx XL184 Médicament: Zanzalintinib Administered as specified in the parent study. Autres noms: XL092 Médicament: Atezolizumab Administered as specified in the parent study. Médicament: Nivolumab Administered as specified in the parent study. Médicament: Abiraterone Administered as specified in the parent study. Médicament: Prednisone Administered as specified in the parent study. Médicament: Enzalutamide Administered as specified in the parent study.

Groupe de participants / Bras

Intervention / Traitement

Expérimental: Cabozantinib/Zanzalintinib

Depending on the study treatment received in the parent study, participants may receive cabozantinib alone or in combination with other agents; zanzalintinib alone or in combination with other agents, or comparator.

Médicament: Cabozantinib